

Real-world budget impact of the adoption of insulin glargine biosimilars in primary care in England (2015-2018)

Supplemental material

Figure S1 Market shares of insulin glargine products in primary care in England




Figure S2 Actual cost of insulin glargine products in primary care in England




Figure S3 Market share of Abasaglar KwikPen®, from the total 3-ml pre-filled pen prescriptions, in December 2015




Figure S4 Market share of Abasaglar KwikPen®, from the total 3-ml pre-filled pen prescriptions, in December 2016




Figure S5 Market share of Abasaglar KwikPen®, from the total 3-ml pre-filled pen prescriptions, in December 2017

